Sanofi (SNYNF) Research & Development (2009 - 2026)
Sanofi (SNYNF) posted Research & Development of -$2.0 billion for Q1 2026, up 77.59% sequentially from -$9.1 billion in Q4 2025, and down 7.54% YoY from -$2.2 billion in Q1 2025.
Sanofi (SNYNF) Research & Development (2009 - 2026) Analysis & Trends
Sanofi (SNYNF) has 18 years of Research & Development data on file, last reported at -$2.0 billion in Q1 2026.
- Quarterly Research & Development fell 7.54% year-over-year to -$2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.8 billion (down 46.03% YoY) and the FY2025 annual result came in at $9.1 billion, up 15.53% from the prior year.
- Research & Development advanced to -$2.0 billion in Q1 2026 per SNYNF's latest filing, from -$9.1 billion in the prior quarter.
- The five-year high for Research & Development was -$1.7 billion in Q1 2022, with the low at -$9.1 billion in Q4 2025.
- Average Research & Development over 5 years is -$3.5 billion, with a median of -$1.9 billion recorded in 2025.
- Year-over-year, Research & Development tumbled 277.33% in 2022 and slipped 0.33% in 2023.
- Sanofi's Research & Development stood at -$6.8 billion in 2022, then slipped by 2.33% to -$7.0 billion in 2023, then dropped by 12.86% to -$7.9 billion in 2024, then fell by 15.53% to -$9.1 billion in 2025, then soared by 77.59% to -$2.0 billion in 2026.
- Business Quant data shows SNYNF's Research & Development at -$2.0 billion in Q1 2026, -$9.1 billion in Q4 2025, and -$6.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.51 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 3.53 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.47 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -3.49 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | -2.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.05 Bn |
| Dec 31, 2025 | -9.13 Bn |
| Sep 30, 2025 | -6.49 Bn |
| Jun 30, 2025 | -2.16 Bn |
| Mar 31, 2025 | -1.90 Bn |
| Dec 31, 2024 | -7.90 Bn |
| Sep 30, 2024 | -1.98 Bn |
| Jun 30, 2024 | -1.79 Bn |
| Mar 31, 2024 | -1.81 Bn |
| Dec 31, 2023 | -7.00 Bn |
| Sep 30, 2023 | -1.81 Bn |
| Jun 30, 2023 | -1.77 Bn |
| Mar 31, 2023 | -1.68 Bn |
| Dec 31, 2022 | -1.86 Bn |
| Sep 30, 2022 | -1.75 Bn |
| Jun 30, 2022 | -1.77 Bn |
| Mar 31, 2022 | -1.67 Bn |
| Dec 31, 2021 | -6.51 Bn |
| Sep 30, 2021 | -1.70 Bn |
| Jun 30, 2021 | -1.68 Bn |